Prestige BioPharma

Company snapshot

Prestige Biopharma Belgium is a biotech organization headquartered in EU. Primary therapeutic focus areas include HER2 Positive Breast Cancer. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (1), phase 1 (1).

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Prestige BioPharma. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Prestige BioPharma.

1. May 26, 2026 Clinical update

   HD201 — Phase 3

2. May 26, 2026 Clinical update

   HD204 — Phase 1

View all clinical trial activity →

• What is Prestige BioPharma?

  Prestige Biopharma Belgium is a biotech organization headquartered in EU. Primary therapeutic focus areas include HER2 Positive Breast Cancer. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials

• Is Prestige BioPharma publicly traded?

  Prestige BioPharma appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Prestige BioPharma develop or market?

  No drug profiles are currently linked to Prestige BioPharma. Pipeline programs may still list investigational assets.

• What are the latest developments for Prestige BioPharma?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Prestige BioPharma focus on?

  Prestige BioPharma focuses on HER2 Positive Breast Cancer based on our analysis of their pipeline programs and drug development activities.